meg, you mentioned again this start-ups. there was a moment when you answered tony's question, you said look, come on, we have five major business units, 150,000 stores. 66 -- 66 countries. i still don't hear anybody talking about how if you can maybe fine tune that, maybe get out of business, and be in mobile, social, cloud, connectivity, i know that those are a more fis issues but when you dealt with salesforce.com at dream force i thought the emphasis would be on at least one of those. i did not get mobile, social, cloud, connect it tifts when i went through your -- connectivity when i went through your presentation yesterday. >> i started out my presentation talking about the innovation that went to the marketplace and led with helian which is our cloud offering distinctive in the market, enables to run work loads in public, private cloud with one click work load portability across those different ens built on open staff and this is a differentiated offering. it is exactly what enterprises need. we're solving a real pain

is it something meg said? >> well, i think, maybe. but it's also a testament to how undervalued hp has been over the past couple of years. keep in mind, even at these levels, it's at about a $65 billion record cap, expected to do $111 billion in revenue for the fiscal year. cash flow from the p.c. business still strong. that business up 7% year over year when a lot of people had given it up. now, it's not growing, but it's still throwing off a lot of cash, which will help fund the turnaround that meg continues to push. look, they also did this fox rate, that's reminiscent of what blackberry is trying to do on handsets. hp's doing this in servers. so a number of things they're trying to get going. they're going to cut, it will add to eps. you want to see growth here in the longer term, and no signs of it in the key areas that matter in the enter price. >> they seem to be fidgeting with a lot parts of the business. meg has continually used this one line which is, the turnaround remains on track. this is a five-year turnaround. she previ

meg terrell is breaking that down from head quarter, meg. >> i will say this year is pharma focus.it's the bier teches that always move. there's names that we're watching closely. there's a data drop a couple weeks ago. one of those names is insight. they have a hot drug in immunotherapy. analysts looking for more data that could reverse the declines we saw on the earlier data. another company we're looking at is clovi as. another one with an approved drug, ariad, who had a new drug on the market. we'll see which patients it might be used best in and there was a big mover in. pharmas. brist bristol-myers. they'll have a lot more data at the meeting they'll be looking for. whether they turn that decline down after they got that down-grade, melissa. >> meg, thanks for that. >> one of the things you see, most of those names peaked in march. >> the big space bio tech is interested in is oncology drugs. the cancer drugs. the real growth opportunities. the thing about playing any one of these, they play at astonishing modules. there are actually a lot of companies not trading in obscene

meg is live in boston with the latest. hey, meg. >> hey, how you doing?h, we talked with ken frazier this morning, the ceo of merck, hours after they announced this deal to sell the over-the-counter health care products unit to bayer. that includes claritin, coppertone and dr. scholl's. ken frazier telling us this is part of a reshaping of the business to focus on areas where they can be a leader. also, of course, a big focus on the pipeline. he highlighted areas like a cancer drug they're very excited about in the hot area of amino oncology, as well as a few other areas. >> hepatitis c, hiv, osteoporosis. there will be a lot of areas of growth for us. of course, behind all of that are still important phase three programs like our late-stage program for alzheimer's. >> now, ken frazier also coming out strongly on u.s. tax policy today against the backdrop of pfizer's $106 billion proposal to buy astrazeneca and take advantage of the lower corporate tax rate. ken frazier telling us pharma companies are in a global war for assets and u.s. companies are at a

meg whitman will appear at 9:00 eastern time. partly in response to a closely watched measure of german business confidence. that's heightened expectations that the european central bank will ease policy next month. we'll see what actually happens. and widely reported but not yet announced deal between apple and beats has reportedly come close to falling apart several times. that is according to tech crunch which says the multibillion dollar deal will go through at some point. it is not after the technology as it is its founders dr. dre. jeff cutmore is hosting a panel at the economic forum held in st. petersburg, russia this morning. putin is delivering a speech. it is a half hour late. we apologize for the lateness we will be getting to. jeff's q and a is about to begin. when it does, we will bring that to you as well. >> and politico's chief economic correspondent, cnbc contributor and he is as far as i'm concerned mr. morning money. you picked up a couple of stories from russia this morning. given that we will have putin on i

cnbc's david faber has an exclusive interview with meg whitman.on "squawk on the street" at 9:00 a.m. eastern a little bit later. >>> gap's first quarter profit was down 22% but that still beat forecasts. the results hurt by weak foreign currencies. the retailer had to step up discounts earlier in the quarter to try and bring in customers when the severe u.s. winter weather affected sales. same-store sales were down around 1%. gap is also affirming its full-year outlook and says it's focused on continued expansion of outside america. shares up 1% after hours. coming up, 1.7% in frankfurt. >>> as for the agenda today in the united states, we've got new home sales out at 10:00 a.m. eastern. sales have forecast to have risen to an annual rate of 418,000, coming on the back of strong existing home sales yesterday. one earnings report of note, the retailer foot locker. after the gain, slim gains we saw for u.s. equities yesterday, we've been up four out of the last five sessions. futures suggest we will continue the trend today. the s&p 500 currently u

i'm so pleased to welcome you all i'm meg the director of the education at the academy and digital learning is one of the major categories we're delighted to be participating in today's program and i really want to thank the mayor and his office in making this happen. that's an amazing morning i'm sorry that you weren't here earlier today to see the youth working on those programs i need inform do more cod pr for those of you you who have not been here we're to explore and sustain life. the claemd - good timing for the class. the academy is the world's only aquarium plan tomorrow and living rain forevers and museum under whereon roof poor we're also the home for major global efforts on bio diversity research and education. the academies leerng program ignites a passion for science and learning by using the same technology that young people are so engaged with is using in narrow daily lives we strive in our digital learning programs to foster the youth driven exploration we know is much more engaging than having young people luring. this is true of the middle school youth. over the past 3 ye

our biotech reporter meg looking at why some drug prices are so high. meg? >> yeah, that's right.ts $84,000, could it actually save money? yes, says gilead science, the drugmaker at the heart of the controversy over high prescription drug prices. the cost of its hepatitis c drug has drawn scrutiny. gilead said it's the value, not the price, that should be the focus. it cured hepatitis c meaning it could save the health care system money in the long term. >> if we can get rid of the liver disease in these patients, with hepatitis c and prevent them from dying of liver cancer, cirrhosis and liver failure, there's no question the cost will be less. >> a liver transplant can cost more than $200,000. patients must then take medicine for the rest of their lives which can cost $40,000 a year or $800,000 over a span of 20 years. gilead argues its drug is priced appropriately, considering the savings over a lifetime. but not everybody agrees. the trade group medicaid health plans for america tweeted me and said using this logic, apple should price iphones at $10,000 because users needn't b

hewlett-packard ceo meg whitman plans to cut 16,000 jobs.fallen for 11 quarters in a row. another company making headlines is ge. the company extending the deadline of its $17 billion offer for alstom's energy unit. politicians are seeking a better offer. ,or more on the takeover battle matt campbell is in london. -- what can bes done during this time? >> this is more time for the french government to essentially try to insert itself into these negotiations between alstom and ge and to give siemens, which is a rival bidder more time to work on its own bid, which some very prominent french politicians have said they would prefer. it is important not to ascribe too much importance to the role of the french government here. obviously, they have the bully pulpit. their pronouncements are reported by the press dutifully, but at the end of the day, alstom is a private company, and at the end of the day will make the decision that they feel is best. it is a game of public perception and political brinkmanship going on around the deal and the result

meg whitman had unveiled a huge number of cuts. lucky 7000. it did not stay at that number for very long will not this year they were talking about 34,000 job cuts by the end of 2014. we have seen a number clean. meg whitman, when asked if this was a confidence issue, said, no, it is not. i am getting deeper into what hp is all about. the more you see the observations, the more you can see a potential to cut costs. a lot of businesses feel very fine. they are ok with the idea of not having clunky hardware in our offices. they're taking advantage of the the cloud. you have hp competing with the likes of google and amazon. i ensure that as you look through the operations and you see one business and another business and they are not necessarily getting the sales they once did, do you need the same sales staff? >> is a great chart that you showed us. it seems like that is a bad place to be, not knowing who will be next. profits were up. where were the bright spots? >> what i find interesting is that for all of the knocks against the pc business,

meg broke the story early for us. meg? industry, buying the over the counter business for $14.2 billion. positioning bayer as the number two player. we had ceo of bayer, maureen decker, reiterating the theme of beefing up areas where they are strong, where they can be the number one and number two players, getting out of areas where they can't compete quite as strongly. and some very well known consumer brands and even historic brands. >> they have tre were men douse consumer loyalty. bayer aspirin, a product we have been selling for over a hundred years now. and claritin, copper tone. those products have great loyalty and provide a very consistent income and cash stream. >> now, in addition to those brands, bayer already sells midol, aleve, one a day, miralax, fafri, dr. scholl's. they are doing something else. they are making a strategic collaboration in cardiovascular. they will pay up front a billion dollars. potential milestone payments of $1.1 billion. $14.2 billion going from bayer to merck. there was a shuffle betw

meg whitman unveiled a huge number of cuts two years ago, at 27,000. it didn't stay at that number very long, within a couple of months the increased by another couple of thousand. 34,000 cutslking by by the end of 2014. they now see that number climbed to 50,000. meg whitman, when asked if this is a confidence issue, said it is not. deep in the weeds about what the company is about. the more you see the operation, the more you can find it the potential to cut costs. that only tells you part of the story. we live in a world where a lot of businesses feel -- are completely ok with the idea of not having clunky hardware in their offices to manage everything. they are taking advantage of the cloud. so you have hp with its servers and software's, and services, competing with the likes of google and amazon, salesforce and workday. i'm sure as you look through the operations and you see one business, another business, they are necessarily getting the sales they once did. do you need the same sales that -- staff? chart there, us a it seems like you has to be

meg, thank you, as well. guys, you want to trade this name and others? we can trade them right in front of the man, too. don't feel compelled to like it just because he's sitting here. >> i've owned the stock in the past. and made money on it. the valuation, you keep waiting for a miss, which hasn't happened. it hasn't given you enough opportunity to get back in, because you just don't want to buy at the top. but clearly, that's been a mistake from a strategy standpoint, because it makes new tops and new highs. so to me, despite what you say, i do think one day somebody will come along and see growth opportunity and pay a nice premium for it, and that also keeps the floor under it. >> like it a lot. like the stock. just like stephen, i wish i'd never sold it. but i'm not in it right now. >> all right. well, after the break, larry macdonald of new edge will call in with a contrarian play you'll want to make up your own mind about. and we're talking to the future of wall street. a recent college grad whose investment club is making complex trades with thei

meg terrell joining us with more on the newest drugs creating buzz and which companies are watching. >> hey, tyler, so one of the big themes we've seen in years past and we'll continue to see is drugs that harness the muren system to fight cancer. now one of the drugs including astrazeneca, merck and roche, you saw some of that last night. another big theme this year is one we've seen over the last year and that is in blood cancer. some of these drugs are moving to chronic leukemia, a big new advance there. finally, i think there will be a lot of discussions around drug prices. of course this is not therapy. but this has been a huge and growing issue as some of the new cancer drugs get very expensive. >> so i understand, meg, there are a lot of studies that come out just before the meeting. what can you tell us about what invest investors as well as consumers can expect to hear from all of that? >> yeah, big data drop, with more than 5,000 studies coming out of the meeting in advance. of course you are seeing a lot of stocks move todd as investors react to that move. now, bristol mey

meg terrell gets some answers. >> reporter: when it was approved in 2001, the cancer drug and others that followed enabled patients to live almost normal life spans, the price about $30,000 a year, now it tripled to $92,000 a year. everybody is taking notice. >> access really is a problem for a lot of patients in relation to these very costly medicines. we sometimes think well, people have insurance and under obamacare there is a lot more coverage. but what that does not take into account is that very often there is a big co-payment that the customer has to come up with that is often many, many hundreds or thousands of dollars. >> reporter: some doctors think about price when prescribing medicines. zol zoltrab didn't work any better but cost twice as much, last year a group of physicians called for lower prices on leukemia drugs. in march, they were asked to explain the price of the drug. it cost $84,000, or about a thousand dollars a day. supporters point out it is a cure for hepatitis c and could save money over the long term. >> some of the price tags put on drugs just appear high

cheering meg whitman's plans to cut jobs. a 11 straight decline in profits.or joining us. get confused with what quarter we are in for hewlett-packard because every single time it is the same. cutting cost, they cannot grow. why is the stock up? >> it is up on further cost cuts, a program that started at 29,000 job cuts is now up to 45,000 or 50,000 jobs. hp does need to get smaller and leaner and more innovative, but having happening -- is an effect on company morale. in beijing cut and move forward, not keep cutting. >> why not do it all at once? >> it is hard to decide. they have lots of different business units in different parts of the market. one cut ando make move forward. that is what they need to do. i have been cutting now for the part of -- the better part of 10 years. to keep they have actual talent, how can they do that when their main focus seems to be cutting cost? >> that is a great point. amid all of these costco and focus on cash flow what is happening is that the underlying i.t. market is changing substantially. there is a dramatic focus on

their laboratory confirmed the infection, the system is working, and i think as meg says, this is not a virus that is spread readily at all in the community, so i think we saw it, and we've got it contained. >> let's move on to another topical question and that the el resurgence of polio in some countries. in truth, in some parts of africa, some strife-ridden war-torn countries, polio has come back. >>> we had it down into the last corners, we were after it, then of course the last countries were the ones that had turbulence. they're also unvac nated and polio can then spread from the corners of the world to new countries once again. all of us should remember, vac nate all your children. >> all right. dr. schaffner, thank you. >> sue, over to you. >> thank you, guys. david faber scoring a big interview with larry robbins. he made a fortune betting on certain health care companies after the supreme court ruling on obamacare. more is culling up next on "power lunch." passenger: road trip buddy. let's put some music on. woman: welcome to learning spanish in the car. passenger: you've got

to meg's credit. this has been a turn-around. she wants to get priced in as a growth turn around story. at what point does it get long? >> you thought they were going to buy a 3d printing and buy -- >> that was long before the 3d printing. i thought this stock was oversold. then it became a turn around story. with meg, i think people gave her enough time. even though she says she needs more time. i think you got to take profits. that's what i did two weeks ago. >> do you think it's enough time? it's a battle ship of -- >> the problem is can she -- that begs the question can it ever work? so if you're saying that yes, she needs more time -- people are starting to question can she turn it around period. >> for hp the tech titan is moving into your mall. josh is live in new jersey with the story. josh. >> melissa, you can see the action behind me. you have got the music and the dancing. but you should have seen the lines this morning. lots of young faces as microsoft was giving away tickets to say mcmoore. i started talking to the k

meg tirrell is on that story. first let ales begin with morgan brennan on the at&t/directv talks. >> hi, tyler, 92 to 94 a share. that's how much at&t could pay for directv if the reports are correct. that would put the price tag at just under $48 billion. the companies aren't commenting, but a deal could be reportedly reaped within the next several weeks. what would at&t actually get for that price? for starters, expanded reach in pay tv, combined it could offer a triple play package to almost 27 million subscribers right now the u-verse products only reaches about 5 million, and they already partner in certain markets. compare that to the 30 million subscribers that cnbc's apparently company comcast would have of its own merger with the time warner cable goes through, plus directv's programming, which exclusively includes the nfl sunday ticket. that contract ends after the upcoming season, but a renewal is reportedly in the works, and expected to come with streaming rights. that's what makes this deal important

. >>> ceo meg whitman saying she's seeing pockets of growth in some of hp's businesses. all right. ty, over to you. >> now to russia and the big newsmaking interview of the day, a global exclusive with the russian president vladimir putin. >>> we were given extraordinary access to putin, and the timing critical. e. >> he was very unhappy about the way it started. he said he would be willing to accept the choice of the russian people. let's play you some of this interview with the russian president. >> translator: the responsibility is to be borne by our european and u.s. partners now they want us to clean up for the mess they created. this is the purpose of sanctions. >> the front-runner at the moments in voting i'm told is mr. poloshenko. he's toll cnbc he would happily engage is he a man you could do business with? >> where is the money? where is the money, you know? it's a business forum. let us be very specific. they owe us 3.5 billion give under the circumstances our money back. you know, that would create very good environment for further discussions. >> did president obama m

meg whitman says they are stabilizing. they have not figured out what their next move is. >> what does oracle do and cisco do over the weekend? they've got to react to this. >> this will save one percent? cent earnings-per-share. they are laying off 50,000 people to save a penny. >> what else do we have? >> we are tracking the developments in a couple of big merger stories. astrazeneca shareholders say the company should continue talks with pfizer after it rejected what pfizer called its last offer which was $117 billion. blackrock is encouraging discussions between the two companies because it owns eight percent of astrazeneca and almost seven percent of pfizer. i guess it can go both ways. >> it's a matter of what price. 53.50 pence was the third and final offer. frenchs agreed to the request to extend the deadline for its plan 17 billion dollar of the austin energy unit. this drama will continue through the month of june. . the french may see better terms siemens of germany may come in for a bit. jobssue is the number o

meg joining us from headquaters.e have the names that option traders see as the next take over target. what are they? we'll name names tonight. you want to know. >> yeah. >> it's a hot sector. >> into a parfrenzy. >> can you give us a trade on pfizer? >> i'll play the game. i don't necessarily know if it's an earnings play. i think it's evaluation play. it's cheap. they made acquisitions before. they bought american home products or whatever they called it for a ridiculous amount of money. they're still trying to play catch up. it was a steal at the time and we said you can go back and archive the fast money tapes. into earnings and out of earnings. >> really impressive. what do you say now. >> burns. >> i just know he's never seen him ever in his life. anyway, i'm going to move on. apple losing it's market share to samsung but it's fighting back by going after the buzz factor by hiring a buzz marketing manager, tim. >> it's depends on how you want to twist the data. apple has 41.7% of the market. that's actually pos

meg, take it away. >> i'm here with chairman and ceo of valeant. you raised a bid today. your stock is down a few percent. maybe you can explain why investors are reacting that way. >> one never knows for sure but what i've read is some were expecting a much higher offer. if we had a higher offer maybe this deal would have been completed more quickly. but we're going to remain financially disciplined. we believe this is a great deal for both sets of shareholders. it's what we've heard from both sets of shareholders. my primary responsibility is for valean sha valeant shareholders. >> you had a lot of questions. is this your last bid. what do you say to that? could you go buyer than this? >> whae we said and consistently said we would be happy to sit down with them and make a final deal. we will not make any other offer until they're willing to sit down with us or go directly to a special meeting. and in terms of our persistence, we were persistpersistent. we will continue to making a question situations. we will continue to move forward. this does not change our business

. >> meg has the news on pfizer, which is back open for trading. meg? >> ye, that's right.zer saying just now that it plans to file for approval of its breast cancer drug palbociclib. we just saw research for that at a meeting and some analysts were skeptical based on the data. but they said they would i a ply in the third quarter based on the face two study, and that may be earlier. this could be a multibillion-dollar drug for pfizer including to a survey of investors. so some big news for pfizer's breast cancer portfolio there. >> meg, thank you so much. we were seeing shares react, jim. >> well, scott, we own the stock. we know about palbociclib. and if you go back a year ago, nobody knew the name or what it did. obviously, breast cancer is a big market. this thing came out of nowhere. so all the people who say, hey, these r&d facilities don't generate anything, this is a great sign. and more to the point, they're filing on phase two data, so they've got something that they really think works here as opposed to waiting for phase three. they think the fda is going to appr

cnbc biotech reporter meg tirrell has that story. hi. >> hi. a lot of attention is being paid to the high cost of drugs, but some industry experts warn there's a flip side. drug prices can get too low with serious consequences. a case in point is antibiotics. they're some of medicine's most successful cures, but antibiotics today are priced at a fraction of the cost of medicines for chronic diseases. increasingly, drugmakers have stopped working in the area because economics don't make sense, leading to what the cdc calls the threat to health, superbugs. some in the industry like biotech analysts warn the scrutiny on drugs that represent cures instead of chronic diseases like rheumatoid arthritis, is stifled. the key is how to balance the cost to patients? >> steve, i mean, you like this space. you're a big investor in it. >> and in the mature companies, and gilead specifically. i think that the government sort of is weighing -- is putting too heavy a hand, and you have to incent these companies to continue with their r&d spending. and that's c

. >> i'm a really big fan of meg whitman. i love hewlett-packard because meg whitman is there. there is hard to come on tv and say i like a stock when they're laying off 50,000 people. that is part of why i like the stock, right? hewlett-packard has been a unwieldy company from cost structure basis. nobody is better at that in my opinion than meg whitman of the when the correction comes hewlett-packard will be beat up more than already. there may be pc sales rebound and windows stops supporting xp. people will look at new pcs. pc loyalists. that will be a good time for them to get into that market. could be -- one of my favorite. buy the correction stocks when the correction happens. liz: well, i would love to see the pc market reinvigorate but it may just, it may just finally find a bottom, how about that? we would be happy with that. let me get to ken. good to have you, ken. talk about your picture for the markets. we know we're coming into a holiday weekend. would i like to throw out this week. it has been awfully thin volume therefore the swings are more dramatic but what d

next speaker, please. >>> my name is meg [speaker not understood]. i work in the department of psychiatry at san francisco general and i've worked there for over 25 years. when i first started, san francisco was a model county and city for providing mental health care. now it's a shadow of itself. we have been cutting services, cutting every budget cycle is cut more and more and more. both inpatient and outpatient. i work specifically at inpatient now. i've worked in outpatient before. if someone cannot be stabilized on an inpatient basis, they're going to be shoved out into the outpatient world and they're going to cycle right back into the inpatient. and that's what we see happening now. we closed two acute units. people are being discharged much quicker than they used to be. they're not being admitted in the first place. i also work in psych emergency. i'm floated down there frequently. and we have to make the decision whether to hospitalize somebody or not and 9 times out of 10 a lot of people that we would have hospitalized even a few years ago

that's the high-level supervisors if it's okay with you i thought i'd ask meg 80 an so walk through the numbers >> thank you. >> as on overview the budget is increasing and important to note of that growth 7.6 million is driven by operating revenues we've split between the designation of futuristic capital. if you're looking at or you've found the slide of the presentation the operating expense has monique explained we're going to accommodate the known growth and the strategic priorities like staffing and other projects. the designation of future capital is trying to meet the capital policy but the other significant part of our growth is the new project the $14.2 million the port entered into the agreements with developers those expenses are offset by the payment its not new to the port but allows us to make the portside expenses in those projects >> a quick question does that include the money to be reallocated based on the heather's cuts. >> this is brown where the cuts are allocated to. >> so this will grow. >> yes. in the second year by a anytime of $5 million and however only 1.3 m

buy buy buy. >> i believe in meg whitman and the turn, i believe pc's at the bottom. believe in 3-d printing. i believe. that, ladies and gentlemen, is the conclusion of "the lightning round." >>> the lightning round is sponsored by -- >>> you think i seem stressed when i come out here hollering like a madman? are you even listening to me? did you wake up and say i'm going to ruin's jim's day? you brought me down, you succeeded. i was doing great. i walked in, now you've made me miserable. are we allowed to light a fire? here? >> come visit us sometime. >> hey, good evening, this is ed from south florida. the cruise capital of america. >> boo-yah. >> i like that. what's up? >> i had a question about rigte aid. >> it's been a -- i went to my rite aid the other day and my picture is up in the wall of the manager's office. hey, dear leader. kind of strange. mcdonald's versus chipotle, aka my modern-day retelling of the tortoise and the hare, because they crave mcdonald's yield. sheesh, mcdonald's feels like a big mac. the hare had an amazing run. they're getting killed b

meg is breaking that down. >> so analysts say this year is a big pharma focus meeting.but, of course,s it the bioteches that always move. and there are names that are watching closely. there was a data drop, unwas insight, they have a improved drug, and a hot drug in immeow know therapy. and analysts looking for more data that could reverse the declines. more data at the meeting. another is clovis. expecting more at the meeting which could be good. and an approved drug, pulled last year due to safety concerns, back on the market. looking to see doses and the patients. and the big mover, that was bristol meyers got downgraded after the data, with the immeow know thera -- immuno therapy. see this if they do that after the downgrade. >> thanks for that. one thing you notice about the charts, most of the names peaked beginning of march. so will this help? >> yeah, the big space in bicycle tech was specifically the oncology drugs. t the cancer drugs in particular. that was the growth opportunities. they trade at astonishing multiples because their speculati speculative. a lo

our average consumer today is getting 50 megs. the vast majority of our new ads are 100 megs.ad to push the speed accelerator. it is a slightly more indebted to markets. that is why 3.1 is hugely important. about 3.1. how transformational is it going to be for consumers? >> from the standpoint of the consumers, the european members of moving very aggressively into the higher speeds and above. cable operators on a roll out basis. we have been able to negotiate a consensus standard globally. it will be able to give you multi-gigabit, 10 gig down, 1 gig up. that is the criteria. existing plan. from the standpoint, there is no digging new digits. the thing you have to do to the whole. everyone is what doing in the able to take that. rather than we get into arguments over fiber, look. fiber miles,e where the largest employer of fiber today. maybe it is better out there. how are you going to serve all of the homes that we serve today? you have to have a technology that works. first order the type partners this year. certification begins and 15. we will see this in the second half of

meg? >> that's right.f drugs is one of the biggest issues weighing on minds of investors in pharma and biotech because they've been going way up. that raises questions about whether they're sustainable. when approved in 2001, gleevec changed the face of chronic mild leukemia. its price about $30,000 a year. a decade later, dplee gleevex's price tripled. that's a growing trend in the pharmaceutical industry. health insurers and congress are taking notice. >> access is a problem for a lot of patients in correlation to these very costly medicines. we sometimes think people have insurance and under obamacare there is a lot more coverage. but what that doesn't take into account is very often there is a very big co-payment that the patient has to come up with that is often many, many hundreds or thousands of dollars. >> reporter: some doctors have started to think about price when prescribing medicines. in 2012, sloan-kettering refuses to use one medicine because it cost twice as much. a group of physicians call

meg? >> that's right. it kicks off today in chicago. it will give us a deep look into where medicine stands in the fight against cancer. it's a disease that affects us all in one way or another. half of all men and a third of all women will get cancer. cancer will cause more than 500,000 deaths. worldwide, of course, the numbers get even bigger. but we have been making progress. now more than two-thirds of people diagnosed with cancer survive beyond five years, that's compared with fewer than half in the first half. the world health organization says that more than 30% of cancer deaths could be prevented by modifying lifestyle, things like smoking, being overweight or obese, not exercising enough and drinking too much alcohol unfortunately. it also spells big business for developing medicine. the global met the market for cancer drugs reached $91 billion in 2013, up from a decade ago. and we'll look at the progress. so what stocks did you watch? the hot area of knew mow oncology is the biggest thing of the meeting. they're watching bris

meg whitman, mitt romney, all the big republicans, pete wilson weighed in for kashkari. republican voters who turn out in the primary going to go along with that? >> what is your read on the evolution of the gop? >> you're a candidate for public office whether you're a democrat or members of the gop, you want as best you can to be more like the people you're asking to vote for you. donnelly is doing a great job because he's talking directly to people that can identify instantly with him. obviously nobody identifies on that side of the aisle with meg whitman. >> this has been the history of the republican party in recent years where in some ways an elite group or something with money comes out on the top of the ticket. and fails to get rid of the support. >> a whitman, fiorina, they have money, don't connect with the grassroots folks. there's not enough country in the country club. >> that's the line he uses. if you go backwards and remember george bush, the president. he was perfect on making the transition from being a part of the country club, yale, into the country. a

our megs mess is consistent f this development is two large sunny side is a nice invade with smaller homes not a neighborhood to build american people numerous house. mr. mark video is being disingenious when he says he's reduced his project it's to the reduced the size of the overall project. the original proposed 40 plus size this on this lot is ridiculous. last fall i declined miss marry making video the project agreement, however, my mom's health declined and i had to prioritize to get her care. because of this i missed the discretionary review and i heard filing an appeal would be the appropriate step the planning department made a error they failed to uphold many of their design outlines and my primary conditioner is to address the scale of building projects. the guideline says quote design the scale of the building to be comparable with the height and depth of the surrounding building this project clearly fails and it's a full store taller than the neighbors and it extend beyond the neighborhood. the negative impact of this failure to respect neighborhood scale is a significan

california candy sciences i've citywide my share of astroids with the games i got to touch and feel greg and meg and alison thank you your staff for hosting us here today it's incredible to be here not only teaches as you what's going on in detail we give us a clue of the future. this is why we decided to take advantage of this and it started yesterday and bring some residence of cork island and the observatory here to a participant with our middle school kids. thank you all for being her. we're succeeding and i know hidrosis draw menu defenses is here we've been investing in our middle schools all of the middle schools as of this year will be open and wified up with ipads throughout the whole middle school (clapping) and generous donations from individuals but we want to take advantage of the fact we have cod can do joe's that are here having fun and part of the our international folks so this is another opportunity to create a presence and maybe some of the industry represented will join us from the academy and promote 24 so kids can understand what the rest of the word is doing. it's gay deve

meg has done a phenomenal job.he stock's had a huge run, we talked about it in the teens, up here at 33 and change, pete, i would take money off the table. >> i still have it on the table. i'm actually thinking about how i want to manipulate myself into more for more upside. when you look at the hybrid cloud and 3-d printing, as she laid out today, i think the stock goes higher. >> at what point does revenue growth shows up? there is none. >> you put this up in the tease. everybody said this thing is dead. i remember at 20 i debated this stock with the bulls and bears. >> it's not dead. when do you need -- >> it has stabilized but now we have to start -- now we want to see some of that. we know there was weakness in pockets, but obviously, we have to see the growth. >> my question, pete, would be, with this quarter they put up, to then come out and cut an additional 11,000 to 16,000 jobs, to me that was kind of the canary in the coal mine there. >> i don't know -- i understand -- >> -- if they're getting better, th

for "nightly business report," i'm meg terrell. >>> nearly one and a half million vehicles are beinglled for safety concerns, but this time ford is the company involved. most of the effective late model cars, 900,000 of them are ford with the torque sensor inside the steering column. also the concerns are taurus sedans being recalled to update the floor mats. >>> more troublepî,Ñ could be oe way for general motors over the recall of two and a half million cars with faulty ignition switches linked to deaths. they say they met with the suspended general motor's engineer who was involved in the recall but pulled off the job in april along with another handful of gm employees. >>> and welcome news for gm after it recalled about 15 million cars so far this year. only eight vehicles earned a superior rating for their collision warning systems and tests conducted by the insurance institute for highway safety. and four of those cars were made by general motors, that includes the only non-luxury make in the bunch, the 2014 chevy, the others topping the ratings, bmw 5 series, the bmwx 5, the b

i'm so pleased to welcome you all i'm meg the director of the education at the academy and digital learnings one of the major categories we're delighted to be participating in today's program and i really want to thank the mayor and his office in making this happen. that's an amazing morning i'm sorry that you weren't here earlier today to see the youth working on those programs i need inform do more cod pr for those of you you who have not been here we're to explore and sustain life. the claemd - good timing for the